Welcome to Medications.com

Boehringer Ingelheim Announces Enrollment Is Complete For The ... - Medical News Today (press release)

The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.0-3.0) in patients with non-valvular atrial ...

http://www.medicalnewstoday.com/a... | Posted: Fri Jan 18 03:07:27 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea